A Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion, and on Insulin Action


About this study

The purpose of the study is to examine the effect of different dosages of Exendin on glucose metabolism, glucagon and insulin secretion, and on insulin action.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

This study has been completed

Inclusion Criteria

  • Healthy
  • Not on any medication other than thyroid hormone replacement or OCP
  • No history of diabetes
  • No prior upper GI surgery

Exclusion Criteria

  • Age < 20 years or > 45
  • Fasting glucose > 100mg/dL
  • Not taking medications other than stable thyroid hormone replacement or oral contraceptives 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer